Large-scale testing (Phase 3)Active Not RecruitingNCT01805271
What this trial is testing
Safety Study of Adding Everolimus to Adjuvant Hormone Therapy in Women With High Risk of Relapse, ER+ and HER2- Primary Breast Cancer, Free of Disease After Receiving at Least One Year of Adjuvant Hormone Therapy
Who this might be right for
Primary Non-metastatic Breast CancerWho Remain Disease-free
UNICANCER 1,278